ThromboGenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps?

With U.S. sales of its eye drug Jetrea lagging, ThromboGenics is casting about for "strategic options." The company boasts Novartis' ($NVS) Alcon unit as a marketing partner outside the U.S. but has been going it alone in the States. Is another partnership in the offing? Release | Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.